A Europe-wide strategy to enhance transplantation of highly sensitized patients on basis of Acceptable HLA mismatches

EUROSTAM is a project financed by the EC (FP7-HEALTH Collaborative project). The project started on 1 december 2012 and was finalized on 30 november 2015.

The project adresses the FP7 workprogramme topic: Innovative approaches to solid organ transplantation.
Main aim of the project is to determine the feasibility and advantage to implement a Europe-wide acceptable mismatch program to facilitate transplantation of highly sensitized patients, who do not have a chance to be transplanted in their own population. The simulation studies on basis of the HLA phenotypes in different European populations will show the theoretical advantage of a Europe-wide acceptable mismatch program. The results of these studies will be published on the EUROSTAM website and in an international peer reviewed journal.

Our goal:

The major objective of the 10 partners in this project is to analyze the feasibility and requirements for a Europe-wide acceptable mismatch program to enhance transplantation of patients with rare HLA phenotypes in their own population. Read more ….


HLA-net is an European network of the HLA diversity for histocompatibility, clinical transplantation, epidemiology and population genetics. Guidelines on how to use the tool are provided with examples of input lines (e.g. for searching...

read more

Allele Frequency Net Database

One of our partners Derek Middleton (Royal Liverpool Hospital) has set up and runs a website, that hosts the Allele Frequency Net Database (AFND). The database is an online repository that contains information on the frequencies of immune...

read more

Kick off meeting – Feb 2013

On February 15, 2013 the EUROSTAM Kick Off meeting took place in the nice atmosphere of Kasteel Oud-Poelgeest in Oegstgeest close to Leiden in the Netherlands. After an introduction by the coordinator of the project Prof. Frans Claas, all participants introduced...

read more

The project has received funding from the European Union’s Seventh Framework Programme [FP7/2007-2013] under grant agreement number HEALTH-F4-2012-305385